![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Protara Therapeutics Inc | NASDAQ:TARA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.03 | -1.55% | 1.91 | 1.88 | 2.04 | 2.04 | 1.87 | 1.97 | 154,345 | 21:52:15 |
“We remain keenly focused on executing on our core mission to deliver effective therapies for rare and specialty diseases amidst these unprecedented times,” Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “With solid financial footing and a strong commitment to the patients we serve, we believe we are well positioned to continue to advance our promising portfolio of late-stage product candidates. We look forward to providing updates on these efforts in the coming months.”
Pipeline Overview
TARA-002
IV Choline Chloride
Corporate Name Change
Business Impact of COVID-19
First Quarter 2020 Results from Operations
A Form 10-Q containing the full financial statements was filed this morning and is available for viewing on the Company’s website at www.Protaratx.com or www.sec.gov.
About Protara Therapeutics, Inc.
Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases who have limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous (IV) Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). For more information, visit www.protaratx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Protara’s business strategy, Protara’s development plans for its product candidates, Protara’s financial footing and the impact of the COVID-19 pandemic on Protara’s business and clinical programs. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties related to Protara’s development programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies; uncertainties related to the actual impacts and length of such impacts caused by the COVID-19 pandemic; having to use cash in ways or on timing other than expected; and the impact of market volatility on cash reserves. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Protara's filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Protara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Company Contact:
Blaine Davis Protara Therapeutics Blaine.Davis@protaratx.com 646-844-0337
PROTARA THERAPEUTICS, INC. | |||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
As of | |||||||
March 31, 2020 | December 31, 2019 | ||||||
(unaudited) | |||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 36,068,736 | $ | 564,124 | |||
Restricted cash | 50,000 | - | |||||
Deferred offering costs | - | 121,712 | |||||
Prepaid expenses and other current assets | 3,562,822 | 78,057 | |||||
Total current assets | 39,681,558 | 763,893 | |||||
Non-current assets: | |||||||
Property and equipment, net | 655,783 | 458,591 | |||||
Right-of-use asset | 391,519 | - | |||||
Goodwill | 29,367,213 | - | |||||
Total assets | $ | 70,096,073 | $ | 1,222,484 | |||
Liabilities and Stockholders' (Deficit) Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 2,649,602 | $ | 715,653 | |||
Accrued expenses | 995,588 | 2,634,790 | |||||
Short-term debt | 1,297,777 | - | |||||
Right-of-use liability, current | 24,727 | - | |||||
Total current liabilities | 4,967,694 | 3,350,443 | |||||
Non-current liabilities: | |||||||
Right-of-use liability, long-term | 386,538 | - | |||||
Total liabilities | 5,354,232 | 3,350,443 | |||||
Commitments and Contingencies | |||||||
Stockholders' Equity (Deficit) | |||||||
Preferred Stock, $0.001 par value, authorized 10,000,000 shares: | |||||||
Series 1 Convertible Preferred Stock, 3,880 and 0 shares authorized at March 31, 2020 | |||||||
and December 31, 2019, respectively, 3,879 and 0 shares issued and outstanding as of | |||||||
March 31, 2020 and December 31, 2019, respectively. | 4 | - | |||||
Common Stock, $0.001 par value, authorized 100,000,000 shares: | |||||||
Common Stock, 5,843,203 and 2,627,533 common shares issued and outstanding as of | |||||||
March 31, 2020 and December 31, 2019, respectively. | 5,843 | 2,628 | |||||
Additional Paid in Capital | 87,577,911 | 10,651,073 | |||||
Accumulated Deficit | (22,841,917 | ) | (12,781,660 | ) | |||
Total Stockholders' Equity (Deficit) | 64,741,841 | (2,127,959 | ) | ||||
Total Liabilities and Stockholders' Equity (Deficit) | $ | 70,096,073 | $ | 1,222,484 | |||
PROTARA THERAPEUTICS, INC. | |||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||
(unaudited) | |||||||
For the Three Months Ended March 31, | |||||||
2020 | 2019 | ||||||
Operating expense: | |||||||
Research & development | $ | 3,064,793 | $ | 1,077,846 | |||
General & administrative | 7,094,832 | 450,210 | |||||
Total operating expenses | 10,159,625 | 1,528,056 | |||||
Operating loss | (10,159,625 | ) | (1,528,056 | ) | |||
Other (income) expense, net | |||||||
Interest (income) expense, net | (99,368 | ) | - | ||||
Total other (income) expense, net | (99,368 | ) | - | ||||
Net Loss | $ | (10,060,257 | ) | $ | (1,528,056 | ) | |
Weighted Average Shares Outstanding, basic and diluted | 5,560,507 | 2,627,533 | |||||
Net loss per share, basic and diluted | $ | (1.81 | ) | $ | (0.58 | ) | |
1 Year Protara Therapeutics Chart |
1 Month Protara Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions